Microsoft's Deputy Chief Technology Officer to be
appointed at Annual Shareholders' Meeting
BOSTON and LAUSANNE, Switzerland, May 31, 2023
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native
software company in the healthcare space and a leader in
data-driven medicine, today announced the nomination of Lila
Tretikov to its Board of Directors. The Board of Directors has
proposed the appointment of Tretikov as a member of the board at
the Annual General Meeting of Shareholders of SOPHiA GENETICS SA on
June 26, 2023.
An award-winning powerhouse in the global technology space,
Tretikov is currently Deputy Chief Technology Officer at Microsoft,
where she previously served as Corporate Vice President in AI.
Before joining Microsoft, Tretikov was CEO and Vice Chair of
Terrawatt for two years and served as CEO of Wikipedia and
Wikimedia.
"Lila is a tremendous leader in the artificial intelligence (AI)
and technology worlds, with robust experience in bringing companies
to scale on a global level. As the founder of several technology
companies throughout her career, her entrepreneurial spirit
combined with her executive leadership skills and comprehensive
experience in AI will complement and add depth to our board and
help take SOPHiA GENETICS to the next level," said Jurgi Camblong,
CEO and Co-Founder of SOPHiA GENETICS.
Once appointed to the SOPHiA GENETICS Board of Directors,
Tretikov will succeed Milton
Silva-Craig and join its current members Jurgi Camblong,
Troy Cox, Kathy Hibbs, Didier
Hirsch, Vincent Ossipow,
Tomer Berkovitz and Jean-Michel
Cosséry in developing the company's sustainable growth and
strategy.
"Throughout my career, I've focused on finding projects that
create outsized socio-economic impact by leveraging cutting-edge
technology. Artificial intelligence has the potential to create
positive change for humanity, and especially in medicine and
biology," said Lila Tretikov. "SOPHiA GENETICS is revolutionizing
the healthcare industry and I am looking forward to working with
them to help further their mission of democratizing data-driven
medicine."
Tretikov currently serves as a board director for Onfido (a
privately-held digital identity tech company). She is also a member
of the board of directors of Volvo Cars (Nasdaq: VOLCAR) and Xylem
(NYSE: XYL).
She graduated from the University of
California, Berkeley with a degree in Computer Science, Art
and Artificial Intelligence, and has completed executive graduate
programs at Stanford University and the
University of Oxford.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-nomination-of-lila-tretikov-to-board-of-directors-301837860.html
SOURCE SOPHiA GENETICS